The interaction between two non-psychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG), which have been reported to act as a 5-hydroxytryptamine 1A (5-HT1A) agonist and antagonist, respectively, was evaluated.
To evaluate the potential of CBG to reverse the anti-nausea, anti-emetic effects of CBD.
Materials and methods
In experiment 1, rats were pre-treated with CBG (0.0, 1, 5, and 10 mg/kg, ip), 15 min prior to being treated with CBD (experiment 1a: VEH or 5 mg/kg, ip) or 8-OH-DPAT (experiment 1b: VEH or 0.01 mg/kg, ip). Thirty minutes later, all rats received a pairing of 0.1% saccharin solution and LiCl (20 ml/kg of 0.15 M, ip). Seventy-two hours later, the rats received a drug-free taste reactivity test with saccharin to evaluate the effects of the treatments on the establishment of conditioned gaping reactions (a model of nausea). As well, conditioned saccharin avoidance was measured. In experiment 2, Suncus murinus were injected with CBG (5 mg/kg, ip) or VEH 15 min prior to CBD (5 mg/kg) or VEH and 30 min later were injected with LiCl (60 ml/kg of 0.15 M, i.p.), and the number of vomiting episodes were measured.
CBD (5 mg/kg) suppressed conditioned gaping in rats and vomiting in shrews, which were reversed by pre-treatment with all doses of CBG. CBG also prevented the anti-nausea effects of 8-OH-DPAT.
Interactions between moderate doses of CBG and CBD may oppose one another at the 5-HT1A receptor in the regulation of nausea and vomiting.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Abrahamov A, Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56:2097–2102
Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Starvi M et al (2008) Antibacterial cannabinoids from Cannabis sativa: a structure–activity study. J Nat Prod 71:1427–1430
Breslin PAS, Grill HJ, Spector AC (1992) A quantitative comparison of taste reactivity behaviors to sucrose before and after lithium chloride pairings: a unidimensional account of palatability. Behav Neurosci 106:820–836
Cascio MG, Gauson LA, Ross RA, Pertwee RG (2010) Evidence that the plant cannabionoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 159:129–141
Colasanti BK (1990) A comparison of the ocular and central effects of delta-9-tetrahydrocannabinol and cannabigerol. J Ocular Pharmacol Ther 6:259–269
Colasanti BK, Craig CR, Allara RD (1984) Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol and cannabigerol. Exper Eye Res 39:251–259
Darmani NA (2001) Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptor in the least shrew. Pharmacol Biochem Behav 69:239–249
Darmani NA, Janoyan JJ, Crim J, Ramirez J (2007) Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur J Pharmacol 563:187–196
De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P et al (2008) Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and malastatin type-8. J Pharmacol Exp Ther 325:1007–1015
Eisohly HN, Turner CE, Clark AM, Eisohly MA (2006) Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. J Pharm Sci 71:1319–1323
Gaoni Y, Mechoulam R (1964a) Isolation, structure, and partial synthesis of an active component of hashish. J Amer Chem Soc 86:1646–1647
Gaoni Y, Mechoulam R (1964b) The structure and synthesis of cannabigerol, a new hashish constituent. Proc Chem Soc 82
Grill HC, Norgren R (1978) The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 143:263–279
Hayakawa K, Mishima K, Abe K, Hasebe N, Takamatsu F, Yasuda H et al (2004) Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. NeuroReport 15:2381–2385
Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004) A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacol 174:254–259
Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L et al (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318:1375–1387
Limebeer CL, Parker LA (1999) Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea. NeuroReport 10:3769–3772
Limebeer CL, Parker LA (2003) The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats. Psychopharmacol 166:120–126
Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, Parker LA (2010) Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharm (in press)
Lucot JB, Crampton GH (1988) 8-OH-DPAT suppresses vomiting in the cat elicited by motion, cisplatin, or xylazine. Pharmacol Biochem Behav 33:627–632
Maor Y, Morowitz M, Gallily R, Mechoulam R (2005) Cannabigerol-dimethyl heptyl (CBG-DMH), a synthetic cannabinoid with hypotensive and vasorelaxant properties. Presented at the symposium of the International Cannabinoid Research Society, Clearwater, FL, June
Mechoulam R (1970) Marihuana chemistry. Science 168:1159–1163
Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S–19S
Mechoulam R, Peters M, Murillo-Rodriquez E, Hanus LO (2007) Cannabidiol—recent advances. Chem Biodiv 4:1678–1692
Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS, Ross SA, Khan IA, ElSohly MA (2010) Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993–2008. J Forensic Sci 55:1209–1217
Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K et al (2005) Cannabidiol prevents infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36:1071–1076
Orr LE, McKernan JF, Bloome B (1980) Antiemetic effect of tetrahydrocannabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 140:1431–1433
Parker LA, Limebeer CL (2008) Cannabinoids and the management of nausea and vomiting. In: Kofalvi A (ed) Cannabinoids and the brain. Springer, New York
Parker LA, Mechoulam R (2003) Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Phsyiol Behav Sci 38:133–145
Parker LA, Mechoulam R, Schlievert C (2002) Cannabidiol, a non-psychoactive component of cannabis, and its dimethylheptyl homolog suppress nausea in an experimental model with rats. NeuroReport 13:567–570
Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P (2003) Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacol 166:156–162
Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004) Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus. Psychopharmacol 171:156–161
Parker LA, Limebeer CL, Kwiatkowska M (2005) Cannabinoids: effects on vomiting and nausea in animal models. In: Mechoulam R (ed) Cannabinoids as therapeutics. Birkhäuser, Switzerland, pp 183–200
Parker LA, Kwiatkowska M, Mechoulam R (2006) Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 87:61–71
Parker LA, Limebeer CL, Rana SA (2008) Conditioned nausea in rats: assessment by conditioned disgust reactions, rather than conditioned taste avoidance. Can J Exp Psychol 62:189–209
Parker, LA., Limebeer CL, Rock EM, Litt DL, Kwiatkowska M., and Piomelli D. (2009) The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine- induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav 97: 121-124
Pertwee RG (2004) In: DiMarzo V (ed) The pharmacology and therapeutic potential of cannabidiol, in cannabinoids. Kluwer, New York
Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA (2008) The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacol 196:389–395
Rock EM, Limebeer CL, Fletcher PJ, Mechoulam R, Parker LA (2010). Cannabidiol (the non-psychoactive component of cannabis) may act as a 5-HT1A auto-receptor agonist to reduce toxin-induced nausea and vomiting. Poster presented at the Society for Neuroscience meeting, San Diego, CA
Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem Res 30:1037–1043
Sallan SE, Zinberg NE, Frei E (1975) Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New Engl J Med 293:795–797
Tramer MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:1–8
Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS et al (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterol 121:767–774
Wilkinson JD, Williamson EM (2007) Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have potential therapeutic value in the treatment of psoriasis. J Dermatol Sci 45:87–92
The following research was supported by research grants from the Natural Sciences and Engineering Research Council (NSERC) of Canada to LAP, a scholarship from NSERC to EMR, and a grant from NIDA (9789) to RM and RGP. For reprints please contact email@example.com.
About this article
Cite this article
Rock, E.M., Goodwin, J.M., Limebeer, C.L. et al. Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology 215, 505–512 (2011). https://doi.org/10.1007/s00213-010-2157-4